Topic : TKIs

Other Topics :

Lower dose may be feasible in older people

Chronic myelogenous leukemia typically affects people later in life, at an age when they may be at greater risk of medication-related side effects. Aging bodies don’t necessarily process medications as well, and the situation can be complicated by other medical conditions, such as hig
Continue Reading →

Sifting through nature’s harvest for solutions

Nature has long been the source of many of the pharmaceuticals used to treat various illnesses, including different types of cancer. An estimated 60% of all cancer drugs originate from natural products, such as trees, shrubs, fruits and vegetables, and marine animals. Perhaps one of t
Continue Reading →

Considering the options when starting treatment

Chronic myelogenous leukemia is now routinely treated with a tyrosine kinase inhibitor (TKI), a family of drugs that blocks leukemia signalling in the bone marrow and arrests the disease process. Three TKIs are approved for use in people newly diagnosed with chronic-phase CML: Gleevec
Continue Reading →

Surviving CML – What about the year to come?

It’s well known that the introduction of tyrosine kinase inhibitors (TKIs, such as Gleevec, Sprycel, Tasigna and Bosulif) have significantly prolonged survival in people with chronic myelogenous leukemia. Where once a CML diagnosis meant an expected survival of only a few years, survi
Continue Reading →

ASH 2016: A half-step may help on the road to TFR

Highlights from the American Society of Hematology (ASH) annual meeting, San Diego CA, December 3-6, 2016 – In previous articles we’ve discussed the most recent information about treatment-free remission (TFR), in which people with a deep molecular response to treatment are able
Continue Reading →

ASH 2016: Stop trials – what if I lose my response?

Highlights from the American Society of Hematology (ASH) annual meeting, San Diego CA, December 3-6, 2016 Part 2 Part 1 of this article summarized the results of recent Stop trials, which found that about 50% of people who try stopping their CML medication can remain in TFR (treatment
Continue Reading →

ASH 2016: Updated results from recent Stop trials

Highlights from the American Society of Hematology (ASH) annual meeting, San Diego CA, December 3-6, 2016 Part 1 Part 2 Perhaps the hottest topic in CML research is whether people can stop taking their medication if they respond well to treatment for an extended period – what has been
Continue Reading →

ASH 2016: “Room for improvement” in CML monitoring, treatment

Highlights from the American Society of Hematology (ASH) annual meeting, San Diego CA, December 3-6, 2016 – A new Canadian study has examined how often people with CML are tested to determine their response to medication (Hillis and colleagues. ASH 2016; abstract 3079). Informat
Continue Reading →

ASH 2016: Stem-cell transplantation: updated results

Highlights from the American Society of Hematology (ASH) annual meeting, San Diego CA, December 3-6, 2016 – With the advent of tyrosine kinase inhibitor (TKI) therapies, stem-cell transplantation (SCT) is less commonly used to treat CML. While it does offer the potential of curi
Continue Reading →

ASH 2016: New treatment trials at ASH 2016

Highlights from the American Society of Hematology (ASH) annual meeting, San Diego CA, December 3-6, 2016 – The annual meeting of the American Society of Hematology is the largest medical congress of the year, and featured the results of several new trials on chronic myelogenous
Continue Reading →